Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

How far have we come with contextual data integration in drug discovery?

Katsila T, Matsoukas MT.

Expert Opin Drug Discov. 2018 Sep;13(9):791-794. doi: 10.1080/17460441.2018.1504767. Epub 2018 Jul 30. No abstract available.

PMID:
30058388
2.

Searching for Clinically Relevant Biomarkers in Geriatric Oncology.

Katsila T, Patrinos GP, Kardamakis D.

Biomed Res Int. 2018 Feb 18;2018:3793154. doi: 10.1155/2018/3793154. eCollection 2018. Review.

3.

Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via Pharmacogenomics.

Sukasem C, Katsila T, Tempark T, Patrinos GP, Chantratita W.

Annu Rev Genomics Hum Genet. 2018 Aug 31;19:329-353. doi: 10.1146/annurev-genom-083115-022324. Epub 2018 Apr 13.

PMID:
29652519
4.

An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients.

Alexopoulou E, Katsila T, Tolia M, Tsoukalas N, Leontsinidis M, Kyrgias G, Kouloulias V, Patrinos GP, Spyropoulou D, Kardamakis D.

Anticancer Res. 2018 Mar;38(3):1615-1622.

PMID:
29491093
5.

The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.

Katsila T, Liontos M, Patrinos GP, Bamias A, Kardamakis D.

EBioMedicine. 2018 Feb;28:43-50. doi: 10.1016/j.ebiom.2018.01.044. Epub 2018 Feb 2. Review.

6.

Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis.

Mitropoulos K, Katsila T, Patrinos GP, Pampalakis G.

OMICS. 2018 Jan;22(1):52-64. doi: 10.1089/omi.2017.0183.

PMID:
29356625
7.

Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients.

Mitropoulos K, Merkouri Papadima E, Xiromerisiou G, Balasopoulou A, Charalampidou K, Galani V, Zafeiri KV, Dardiotis E, Ralli S, Deretzi G, John A, Kydonopoulou K, Papadopoulou E, di Pardo A, Akcimen F, Loizedda A, Dobričić V, Novaković I, Kostić VS, Mizzi C, Peters BA, Basak N, Orrù S, Kiskinis E, Cooper DN, Gerou S, Drmanac R, Bartsakoulia M, Tsermpini EE, Hadjigeorgiou GM, Ali BR, Katsila T, Patrinos GP.

Hum Genomics. 2017 Dec 8;11(1):30. doi: 10.1186/s40246-017-0126-2.

8.

Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment.

Pisanu C, Katsila T, Patrinos GP, Squassina A.

Pharmacogenomics. 2018 Jan;19(2):129-143. doi: 10.2217/pgs-2017-0111. Epub 2017 Dec 4. Review.

PMID:
29199496
9.

Advancing Global Precision Medicine: An Overview of Genomic Testing and Counseling Services in Malaysia.

Balasopoulou A, Mooy FM, Baker DJ, Mitropoulou C, Skoufas E, Bulgiba A, Katsila T, Patrinos GP.

OMICS. 2017 Dec;21(12):733-740. doi: 10.1089/omi.2017.0136. Epub 2017 Nov 27. Review.

PMID:
29173101
10.

Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy.

Mitropoulos K, Cooper DN, Mitropoulou C, Agathos S, Reichardt JKV, Al-Maskari F, Chantratita W, Wonkam A, Dandara C, Katsila T, Lopez-Correa C, Ali BR, Patrinos GP.

OMICS. 2017 Nov;21(11):647-657. doi: 10.1089/omi.2017.0141.

PMID:
29140767
11.

Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients.

Chondrou V, Kolovos P, Sgourou A, Kourakli A, Pavlidaki A, Kastrinou V, John A, Symeonidis A, Ali BR, Papachatzopoulou A, Katsila T, Patrinos GP.

Hum Genomics. 2017 Oct 23;11(1):24. doi: 10.1186/s40246-017-0120-8.

12.

Cancer Genomics and Public Health.

Malats N, Katsila T, Patrinos GP.

Public Health Genomics. 2017;20(2):67-69. doi: 10.1159/000479811. Epub 2017 Aug 24. No abstract available.

PMID:
28848209
13.

Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping.

Vermeulen C, Geeven G, de Wit E, Verstegen MJAM, Jansen RPM, van Kranenburg M, de Bruijn E, Pulit SL, Kruisselbrink E, Shahsavari Z, Omrani D, Zeinali F, Najmabadi H, Katsila T, Vrettou C, Patrinos GP, Traeger-Synodinos J, Splinter E, Beekman JM, Kheradmand Kia S, Te Meerman GJ, Ploos van Amstel HK, de Laat W.

Am J Hum Genet. 2017 Sep 7;101(3):326-339. doi: 10.1016/j.ajhg.2017.07.012. Epub 2017 Aug 24.

14.

Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation.

Katsila T, Matsoukas MT, Patrinos GP, Kardamakis D.

OMICS. 2017 Aug;21(8):429-439. doi: 10.1089/omi.2017.0087. Review.

PMID:
28816643
15.

Exploring public genomics data for population pharmacogenomics.

Lakiotaki K, Kanterakis A, Kartsaki E, Katsila T, Patrinos GP, Potamias G.

PLoS One. 2017 Aug 3;12(8):e0182138. doi: 10.1371/journal.pone.0182138. eCollection 2017.

16.

Exosomes: A Cancer Theranostics Road Map.

Panagiotara A, Markou A, Lianidou ES, Patrinos GP, Katsila T.

Public Health Genomics. 2017;20(2):116-125. doi: 10.1159/000478253. Epub 2017 Jul 20. Review.

17.

Application of the DruGeVar Database in Cancer Genomics and Pharmacogenomics.

Sarris K, Komianou A, Patrinos GP, Katsila T.

Public Health Genomics. 2017;20(2):142-147. doi: 10.1159/000478254. Epub 2017 Jul 14.

PMID:
28704821
18.

Editorial: (Pharmaco)Metabolomics in Drug Discovery and Individualisation of Treatment.

Katsila T, Patrinos GP.

Curr Pharm Des. 2017;23(14):2027. doi: 10.2174/1381612823999170301112648. No abstract available.

PMID:
28701139
19.

Key Pharmacogenomic Considerations for Sickle Cell Disease Patients.

Kolliopoulou A, Stratopoulos A, Siamoglou S, Sgourou A, Ali BR, Papachatzopoulou A, Katsila T, Patrinos GP.

OMICS. 2017 Jun;21(6):314-322. doi: 10.1089/omi.2017.0058. Epub 2017 May 9.

PMID:
28486096
20.

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017.

21.

Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies.

Viennas E, Komianou A, Mizzi C, Stojiljkovic M, Mitropoulou C, Muilu J, Vihinen M, Grypioti P, Papadaki S, Pavlidis C, Zukic B, Katsila T, van der Spek PJ, Pavlovic S, Tzimas G, Patrinos GP.

Nucleic Acids Res. 2017 Jan 4;45(D1):D846-D853. doi: 10.1093/nar/gkw949. Epub 2016 Oct 18.

22.

Novel genetic risk variants for pediatric celiac disease.

Balasopoulou A, Stanković B, Panagiotara A, Nikčevic G, Peters BA, John A, Mendrinou E, Stratopoulos A, Legaki AI, Stathakopoulou V, Tsolia A, Govaris N, Govari S, Zagoriti Z, Poulas K, Kanariou M, Constantinidou N, Krini M, Spanou K, Radlovic N, Ali BR, Borg J, Drmanac R, Chrousos G, Pavlovic S, Roma E, Zukic B, Patrinos GP, Katsila T.

Hum Genomics. 2016 Oct 24;10(1):34.

23.

Pharmacometabolomics Informs Viromics toward Precision Medicine.

Balasopoulou A, Patrinos GP, Katsila T.

Front Pharmacol. 2016 Oct 27;7:411. eCollection 2016.

24.

Pharmacogenomics education and research at the Department of Pharmacy, University of Patras, Greece.

Patrinos GP, Katsila T.

Pharmacogenomics. 2016 Oct 28. [Epub ahead of print]

PMID:
27790924
25.

Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacy.

Gravia A, Chondrou V, Kolliopoulou A, Kourakli A, John A, Symeonidis A, Ali BR, Sgourou A, Papachatzopoulou A, Katsila T, Patrinos GP.

Pharmacogenomics. 2016 Oct 21. [Epub ahead of print]

PMID:
27767389
26.

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172595.

27.

ePGA: A Web-Based Information System for Translational Pharmacogenomics.

Lakiotaki K, Kartsaki E, Kanterakis A, Katsila T, Patrinos GP, Potamias G.

PLoS One. 2016 Sep 15;11(9):e0162801. doi: 10.1371/journal.pone.0162801. eCollection 2016.

28.

Computational approaches in target identification and drug discovery.

Katsila T, Spyroulias GA, Patrinos GP, Matsoukas MT.

Comput Struct Biotechnol J. 2016 May 7;14:177-84. doi: 10.1016/j.csbj.2016.04.004. eCollection 2016. Review.

29.

Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease.

Katsila T, Konstantinou E, Lavda I, Malakis H, Papantoni I, Skondra L, Patrinos GP.

EBioMedicine. 2016 Feb 2;5:40-5. doi: 10.1016/j.ebiom.2016.02.001. eCollection 2016 Mar. Review.

30.

Nutrigenomics: A controversy.

Pavlidis C, Patrinos GP, Katsila T.

Appl Transl Genom. 2015 Feb 14;4:50-3. doi: 10.1016/j.atg.2015.02.003. eCollection 2015 Mar.

31.

Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.

Chalikiopoulou C, Tavianatou AG, Sgourou A, Kourakli A, Kelepouri D, Chrysanthakopoulou M, Kanelaki VK, Mourdoukoutas E, Siamoglou S, John A, Symeonidis A, Ali BR, Katsila T, Papachatzopoulou A, Patrinos GP.

Pharmacogenomics. 2016 Mar;17(4):393-403. doi: 10.2217/pgs.16.1. Epub 2016 Feb 19.

PMID:
26895070
32.

Development and validation of a UHPLC-UV method for the determination of a prostate secretory protein 94-derived synthetic peptide (PCK3145) in human plasma and assessment of its stability in human plasma.

El Mubarak MA, Leontari I, Danika C, Katsila T, Sivolapenko G.

Biomed Chromatogr. 2016 Sep;30(9):1476-80. doi: 10.1002/bmc.3708. Epub 2016 Mar 21.

PMID:
26892539
33.
34.

Functional Analysis of an (A)γ-Globin Gene Promoter Variant (HBG1: g.-225_-222delAGCA) Underlines Its Role in Increasing Fetal Hemoglobin Levels Under Erythropoietic Stress.

Ugrin M, Stojiljkovic M, Zukic B, Klaassen K, Katsila T, Vasiljevic J, Dokmanovic L, Janic D, Patrinos GP, Pavlovic S.

Hemoglobin. 2016;40(1):48-52. doi: 10.3109/03630269.2015.1107842. Epub 2015 Nov 16.

PMID:
26575252
35.

TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner.

Kotur N, Dokmanovic L, Janic D, Stankovic B, Krstovski N, Tosic N, Katsila T, Patrinos GP, Zukic B, Pavlovic S.

Pharmacogenomics. 2015;16(15):1701-12. doi: 10.2217/pgs.15.109. Epub 2015 Sep 28.

PMID:
26411491
36.

Meta-Analysis of Genes in Commercially Available Nutrigenomic Tests Denotes Lack of Association with Dietary Intake and Nutrient-Related Pathologies.

Pavlidis C, Lanara Z, Balasopoulou A, Nebel JC, Katsila T, Patrinos GP.

OMICS. 2015 Sep;19(9):512-20. doi: 10.1089/omi.2015.0109.

PMID:
26348710
37.

The Implications of Metabotypes for Rationalizing Therapeutics in Infants and Children.

Katsila T, Patrinos GP.

Front Pediatr. 2015 Jul 29;3:68. doi: 10.3389/fped.2015.00068. eCollection 2015. Review. No abstract available.

38.

Identification of a novel homozygous SPG7 mutation by whole exome sequencing in a Greek family with a complicated form of hereditary spastic paraplegia.

Daoud H, Papadima EM, Ouled Amar Bencheikh B, Katsila T, Dionne-Laporte A, Spiegelman D, Dion PA, Patrinos GP, Orrù S, Rouleau GA.

Eur J Med Genet. 2015 Nov;58(11):573-7. doi: 10.1016/j.ejmg.2015.08.001. Epub 2015 Aug 7.

PMID:
26260707
39.

Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach.

Karageorgos I, Mizzi C, Giannopoulou E, Pavlidis C, Peters BA, Zagoriti Z, Stenson PD, Mitropoulos K, Borg J, Kalofonos HP, Drmanac R, Stubbs A, van der Spek P, Cooper DN, Katsila T, Patrinos GP.

Hum Genomics. 2015 Jun 20;9:12. doi: 10.1186/s40246-015-0034-2.

40.

Whole genome sequencing in pharmacogenomics.

Katsila T, Patrinos GP.

Front Pharmacol. 2015 Mar 26;6:61. doi: 10.3389/fphar.2015.00061. eCollection 2015.

41.

Assessment of the pharmacogenomics educational environment in Southeast Europe.

Pisanu C, Tsermpini EE, Mavroidi E, Katsila T, Patrinos GP, Squassina A.

Public Health Genomics. 2014;17(5-6):272-9. doi: 10.1159/000366461. Epub 2014 Oct 17.

PMID:
25341999
42.

Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.

Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J.

Clin Cancer Res. 2014 Dec 15;20(24):6346-56. doi: 10.1158/1078-0432.CCR-14-0361. Epub 2014 Oct 16.

43.

DruGeVar: an online resource triangulating drugs with genes and genomic biomarkers for clinical pharmacogenomics.

Dalabira E, Viennas E, Daki E, Komianou A, Bartsakoulia M, Poulas K, Katsila T, Tzimas G, Patrinos GP.

Public Health Genomics. 2014;17(5-6):265-71. doi: 10.1159/000365895. Epub 2014 Sep 9.

PMID:
25228099
44.

Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.

Gravia A, Chondrou V, Sgourou A, Papantoni I, Borg J, Katsila T, Papachatzopoulou A, Patrinos GP.

Pharmacogenomics. 2014 Jul;15(10):1355-64. doi: 10.2217/pgs.14.101. Review.

PMID:
25155936
45.

Personalized pharmacogenomics profiling using whole-genome sequencing.

Mizzi C, Peters B, Mitropoulou C, Mitropoulos K, Katsila T, Agarwal MR, van Schaik RH, Drmanac R, Borg J, Patrinos GP.

Pharmacogenomics. 2014 Jun;15(9):1223-34. doi: 10.2217/pgs.14.102.

PMID:
25141897
46.

Deciphering next-generation pharmacogenomics: an information technology perspective.

Potamias G, Lakiotaki K, Katsila T, Lee MT, Topouzis S, Cooper DN, Patrinos GP.

Open Biol. 2014 Jul;4(7). pii: 140071. doi: 10.1098/rsob.140071.

47.

Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion.

Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J.

J Proteome Res. 2014 Jul 15. [Epub ahead of print]

PMID:
24897304
48.

Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.

Voutsas IF, Pistamaltzian N, Tsiatas ML, Skopeliti M, Katsila T, Mavrothalassiti I, Spyrou S, Dimopoulos MA, Tsitsilonis OE, Bamias A.

Eur J Cancer. 2013 May;49(7):1706-14. doi: 10.1016/j.ejca.2012.11.037. Epub 2012 Dec 28.

PMID:
23276721
49.

Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties.

Laimou D, Katsila T, Matsoukas J, Schally A, Gkountelias K, Liapakis G, Tamvakopoulos C, Tselios T.

Eur J Med Chem. 2012 Dec;58:237-47. doi: 10.1016/j.ejmech.2012.09.043. Epub 2012 Oct 4.

PMID:
23127987
50.

Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.

Katsila T, Siskos AP, Tamvakopoulos C.

Mass Spectrom Rev. 2012 Jan-Feb;31(1):110-33. doi: 10.1002/mas.20340. Epub 2011 Jun 22. Review.

PMID:
21698655

Supplemental Content

Loading ...
Support Center